fda deadline for compounded semaglutide The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new (Wegovy) weight-loss pill from the Compounded Semaglutide Manufacturing Ban

Real care, real people, real partnership

Compounding pharmacies are not required to track, evaluate, or report adverse events to the FDA

Patients with conditions like chronic fatigue syndrome or fibromyalgia might be interested in exploring the use of glutathione in their management plans, in conjunction with their healthcare provider's guidance It is important, however, for both patients and prescribers to note that while there is anecdotal and initial scientific support for these uses, the established evidence is limited, and further research is required to fully understand the efficacy and safety of glutathione in these contexts

Within a week of starting a GLP-1, everything changed